Oric Pharmaceuticals
ORIC
83 hedge funds and large institutions have $353M invested in Oric Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 18 closing their positions.
87% more capital invested
Capital invested by funds: $189M → $353M (+$165M)
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
27.71% more ownership
Funds ownership: 73.28% → 100.99% (+28%)
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
19% more funds holding
Funds holding: 70 → 83 (+13)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
68% less call options, than puts
Call options by funds: $336K | Put options by funds: $1.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$24.3M |
| 2 |
VA
VR Adviser
New York
|
+$12.2M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$12.2M |
| 4 |
BlackRock
New York
|
+$10.7M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$6.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$8.01M |
| 2 |
Millennium Management
New York
|
-$6.31M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.56M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29M |
| 5 |
O
OrbiMed
New York
|
-$1.17M |
ORIC Hedge Fund Activity: Q2 2023 in Review
83 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2023, worth a combined $353M — up 87% from $189M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ORIC positions and 18 closed out — a net gain of 13 holders — while 25 added to existing stakes and 20 trimmed.
The largest buyer was Nextech Invest, opening a new position worth an estimated $24.3M. The largest seller was Suvretta Capital Management, cutting an estimated $8.01M.
- 83 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2023, up from 70 in Q1 2023.
- Funds reported $353M of Oric Pharmaceuticals stock for Q2 2023, up 87% quarter-over-quarter.
- 31 funds opened new Oric Pharmaceuticals positions in Q2 2023 and 18 closed out, a net change of +13 holders.
- The largest Oric Pharmaceuticals buyer in Q2 2023 was Nextech Invest, an estimated $24.3M added.
- The largest Oric Pharmaceuticals seller in Q2 2023 was Suvretta Capital Management, an estimated $8.01M sold.
Based on aggregated 13F filings for Q2 2023.